Inhaled muco-trapping antibody therapy for RSV (IN-002)
Official title: Pharmacokinetics analysis from first-in-human study of IN-002, a potent inhaled muco-trapping antibody therapy for RSV
Funded at Inhalon Biopharma, INC. · NIH-11123509 · Data updated 2026-11-12
This project tests an inhaled antibody called IN-002 that aims to trap and clear RSV from the airways to help infants, children, and adults at risk of severe RSV.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Inhalon Biopharma, INC. NIH-funded |
| Lab location | 1 site (Morrisville, UNITED STATES) |
| Project start | June 21, 2024 |
| Project end | May 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $1,024,945 |
| NIH project number | 5R44AI186834-02 |
| Project ID | NIH-11123509 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates would be adults or older children who meet the study's eligibility criteria and are either infected with RSV or at increased risk for severe RSV.
✕Less likely to help
People without airway RSV infection, those already critically ill in the hospital, or those with known allergies to antibody products may not receive benefit from this early-phase work.
What this research studies
If I join, I would inhale IN-002 using a handheld device so the antibody goes straight to my airways where RSV lives. The team will measure how long the antibody stays in airway mucus and blood and monitor safety and side effects. IN-002 is designed to stick to the RSV F protein and trap virus particles in mucus so natural clearance can remove them. Early work will focus on first-in-human pharmacokinetics and safety, building toward use in people most affected by RSV.
Why it matters
Potential benefit: If successful, this could shorten or prevent RSV lung infections by clearing the virus more quickly from the airways.
How similar studies have gone: Systemic monoclonal antibodies have helped prevent severe RSV, but inhaled muco-trapping antibodies are a newer approach with promising lab and animal results and limited human data so far.
Where this research is happening
-
Inhalon Biopharma, INC.
Morrisville, United States Active
Researchers
- Principal investigator: Scott, David W — Inhalon Biopharma, INC.
- Study coordinator: Scott, David W
Related research
Other NIH-funded projects on the same topics.
-
Sub-second acetylcholine release in the brain for Alzheimer’s dementia
A small, quick stimulations-based study aims to boost a brain chemical called acetylcholine to help people with Alzheimer’s disease by using a targeted brain stimulation approach.
-
Understanding how broadly neutralizing antibodies may help HIV cure trials
A study at UC San Francisco looks at how antibody medicines behave in people on and off HIV therapy to help design better cure strategies.
-
Improving HIV-related brain infections by studying how drugs reach the brain
This grant looks at how well drugs reach the brain and spine to treat HIV-related infections like cryptococcal meningitis and TB meningitis in people with AIDS.
-
Transdermal delivery patch for zanamivir to treat influenza in patients
A new skin patch delivers zanamivir to people with flu or at risk of flu, aiming for easier, safer treatment than pills.
-
Chesapeake-Ohio Pharmacokinetics Core supports cancer drug testing
A collaborative core lab helps researchers study how cancer drugs behave in the body to improve clinical trials and patient care.
-
Urine color test to check tuberculosis drug levels in children and adults
This project uses a simple urine color test to see whether children and adults with TB are getting enough of key TB medicines like rifampin.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.